Protalix BioTherapeutics Inc (AMEX:PLX) shares, rose in value on Friday, March 28, without any change to the previous day’s close as strong demand from buyers drove the stock to $2.58.
Actively observing the price movement in the last trading, the stock closed the session at $2.58, falling within a range of $2.525 and $2.62. The value of beta (5-year monthly) was 0.725 whereas the PE ratio was 98.10 over 12-month period. Referring to stock’s 52-week performance, its high was $2.76, and the low was $0.82. On the whole, PLX has fluctuated by 10.73% over the past month.
With the market capitalization of Protalix BioTherapeutics Inc currently standing at about $201.32 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Mar-16.
Projections by analysts suggest varying estimates for the company’s quarterly revenue. Analysts have estimated the company’s revenue for the quarter at 80.49M, with a low estimate of 21.6M and a high estimate of 21.6M. Wall Street analysts also predicted that the company’s y-o-y revenues would reach 21.6M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that PLX’s technical picture suggests that short-term indicators denote the stock is a 50% Buy on average. However, medium-term indicators have put the stock in the category of 100% Buy while long-term indicators on average have been pointing out that it is a 100% Buy.
The stock’s technical analysis shows that the price of PLX currently trading nearly 8.36% and 6.55% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 59.31, while the 7-day volatility ratio is showing 4.20% which for the 30-day chart, stands at 5.51%. Furthermore, Protalix BioTherapeutics Inc (PLX)’s beta value is 0.47, and its average true range (ATR) is 0.13.
A comparison of Protalix BioTherapeutics Inc (PLX) with its peers suggests the former has fared considerably weaker in the market. PLX showed an intraday change of 0.00% in last session, and over the past year, it grew by 111.48%%.
Data on historical trading for Protalix BioTherapeutics Inc (AMEX:PLX) indicates that the trading volumes over the past 10 days have averaged 0.81 and over the past 3 months, they’ve averaged 708.22K. According to company’s latest data on outstanding shares, there are 75.85 million shares outstanding.
Nearly 7.51% of Protalix BioTherapeutics Inc’s shares belong to company insiders and institutional investors own 6.63% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 0.65 million shares as on 2025-03-14, resulting in a short ratio of 0.99. According to the data, the short interest in Protalix BioTherapeutics Inc (PLX) stood at 87.00 of shares outstanding as of 2025-03-14; the number of short shares registered in 2025-02-14 reached 4.79 million. The stock has risen by 37.23% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the PLX stock heading into the next quarter.
